{"transactions":[{"id":2837,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":2694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":2694},"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2836,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023."}],"balance_after":1750,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2835,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":1591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024."}],"balance_after":3182,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1591},"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2834,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":false,"shares":3069,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026."}],"balance_after":9206,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":3069},"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2833,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":31150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2026."}],"balance_after":31150,"derivative":{"exercise_price":79.28,"expiration_date":"2036-08-31","underlying":"Class A Ordinary Share","underlying_shares":31150},"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2832,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"grant","planned":false,"acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2026."}],"balance_after":7800,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2831,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":4404,"price":79.28,"value":349149.12,"ownership":{"direct":true},"balance_after":20854,"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2830,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":3069,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":25258,"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2829,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":1591,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":22189,"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2828,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":20598,"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":2827,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-09-03T20:49:57.000Z","date":"2026-09-01","kind":"exercise","planned":false,"acquired":true,"shares":2694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":18848,"source":{"system":"sec-edgar","filing":"0001835458-26-000012","document":"form4-09032026_080953.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000012/form4-09032026_080953.xml","form_type":"4"}},{"id":812620,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-04-08T20:44:12.000Z","date":"2026-04-07","kind":"exercise","planned":false,"acquired":false,"shares":2694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":2694},"source":{"system":"sec-edgar","filing":"0001835458-26-000010","document":"form4-04082026_080407.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000010/form4-04082026_080407.xml","form_type":"4"}},{"id":812619,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-04-08T20:44:12.000Z","date":"2026-04-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1303,"price":48.94,"value":63768.82,"ownership":{"direct":true},"balance_after":16154,"source":{"system":"sec-edgar","filing":"0001835458-26-000010","document":"form4-04082026_080407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000010/form4-04082026_080407.xml","form_type":"4"}},{"id":812618,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-04-08T20:44:12.000Z","date":"2026-04-07","kind":"exercise","planned":false,"acquired":true,"shares":2694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":17457,"source":{"system":"sec-edgar","filing":"0001835458-26-000010","document":"form4-04082026_080407.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000010/form4-04082026_080407.xml","form_type":"4"}},{"id":816677,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":1846,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2025."}],"balance_after":5536,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1846},"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816676,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":1591,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2024."}],"balance_after":3182,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1591},"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816675,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of the grant, April 1, 2023."}],"balance_after":1750,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816674,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance Share Unit","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":15600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2029, unless such date falls on a non-business date, in which case the next business date shall apply."}],"balance_after":15600,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":15600},"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816673,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":7800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2026, and each yearly anniversary thereafter."}],"balance_after":7800,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":7800},"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816672,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"grant","planned":false,"acquired":true,"shares":31150,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2026."}],"balance_after":31150,"derivative":{"exercise_price":48.13,"expiration_date":"2036-03-31","underlying":"Class A Ordinary Share","underlying_shares":31150},"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816671,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2510,"price":48.13,"value":120806.3,"ownership":{"direct":true},"balance_after":14763,"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":816670,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-04-03T20:40:09.000Z","date":"2026-04-01","kind":"exercise","planned":false,"acquired":true,"shares":5187,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":17273,"source":{"system":"sec-edgar","filing":"0001835458-26-000008","document":"form4-04032026_080402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000008/form4-04032026_080402.xml","form_type":"4"}},{"id":848851,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":10360,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2024."}],"balance_after":22790,"derivative":{"exercise_price":26.74,"expiration_date":"2034-08-31","underlying":"Class A Ordinary Share","underlying_shares":10360},"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848850,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":13813,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2024."}],"balance_after":19337,"derivative":{"exercise_price":18.06,"expiration_date":"2034-03-31","underlying":"Class A Ordinary Share","underlying_shares":13813},"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848849,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":10513,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023."}],"balance_after":18396,"derivative":{"exercise_price":17.76,"expiration_date":"2033-08-31","underlying":"Class A Ordinary Share","underlying_shares":10513},"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848848,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":false,"shares":2036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":22.89,"expiration_date":"2031-03-15","underlying":"Class A Ordinary Share","underlying_shares":2036},"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848847,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":18741,"price":46.24,"value":866583.84,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $45.89 and $46.79. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price."}],"balance_after":12086,"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848846,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"sale","planned":true,"acquired":false,"shares":17981,"price":45.58,"value":819573.98,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $44.885 and $45.88. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":30827,"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848845,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":10360,"price":26.74,"value":277026.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":48808,"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848844,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":13813,"price":18.06,"value":249462.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":38448,"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848843,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":10513,"price":17.76,"value":186710.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":24635,"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":848842,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-03-11T20:38:02.000Z","date":"2026-03-09","kind":"exercise","planned":true,"acquired":true,"shares":2036,"price":22.89,"value":46604.04,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":14122,"source":{"system":"sec-edgar","filing":"0001835458-26-000006","document":"form4-03112026_080357.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000006/form4-03112026_080357.xml","form_type":"4"}},{"id":910095,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-02-11T21:38:32.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":false,"shares":2471,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":16.9,"expiration_date":"2031-04-25","underlying":"Class A Ordinary Share","underlying_shares":2471},"source":{"system":"sec-edgar","filing":"0001835458-26-000004","document":"form4-02112026_090228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000004/form4-02112026_090228.xml","form_type":"4"}},{"id":910094,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2026-02-11T21:38:32.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":false,"shares":8374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":12.97,"expiration_date":"2031-09-01","underlying":"Class A Ordinary Share","underlying_shares":8374},"source":{"system":"sec-edgar","filing":"0001835458-26-000004","document":"form4-02112026_090228.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000004/form4-02112026_090228.xml","form_type":"4"}},{"id":910093,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-02-11T21:38:32.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":8731,"price":43.72,"value":381719.32,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $43.35 and $44.18. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price."}],"balance_after":12086,"source":{"system":"sec-edgar","filing":"0001835458-26-000004","document":"form4-02112026_090228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000004/form4-02112026_090228.xml","form_type":"4"}},{"id":910092,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-02-11T21:38:32.000Z","date":"2026-02-09","kind":"sale","planned":true,"acquired":false,"shares":9114,"price":42.85,"value":390534.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $42.35 and $43.345. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff fullinformation regarding the number of Shares sold at each price."}],"balance_after":20817,"source":{"system":"sec-edgar","filing":"0001835458-26-000004","document":"form4-02112026_090228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000004/form4-02112026_090228.xml","form_type":"4"}},{"id":910091,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-02-11T21:38:32.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":true,"shares":2471,"price":16.9,"value":41759.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":29931,"source":{"system":"sec-edgar","filing":"0001835458-26-000004","document":"form4-02112026_090228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000004/form4-02112026_090228.xml","form_type":"4"}},{"id":910090,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-02-11T21:38:32.000Z","date":"2026-02-09","kind":"exercise","planned":true,"acquired":true,"shares":8374,"price":12.97,"value":108610.78,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":27460,"source":{"system":"sec-edgar","filing":"0001835458-26-000004","document":"form4-02112026_090228.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000004/form4-02112026_090228.xml","form_type":"4"}},{"id":942261,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2026-01-09T21:35:42.000Z","date":"2026-01-08","kind":"sale","planned":true,"acquired":false,"shares":12000,"price":41.89,"value":502680.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.44 and $42.24. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":19086,"source":{"system":"sec-edgar","filing":"0001835458-26-000002","document":"form4-01092026_090138.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545826000002/form4-01092026_090138.xml","form_type":"4"}},{"id":974560,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":10512,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023."}],"balance_after":14016,"derivative":{"exercise_price":10.76,"expiration_date":"2033-03-31","underlying":"Class A Ordinary Share","underlying_shares":10512},"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":974559,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":16165,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022."}],"balance_after":12123,"derivative":{"exercise_price":11.97,"expiration_date":"2032-08-31","underlying":"Class A Ordinary Share","underlying_shares":16165},"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":974558,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":false,"shares":16164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022."}],"balance_after":5388,"derivative":{"exercise_price":11.1,"expiration_date":"2032-04-06","underlying":"Class A Ordinary Share","underlying_shares":16164},"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":974557,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"sale","planned":true,"acquired":false,"shares":42841,"price":41.49,"value":1777473.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $41.20 and $42.08. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":31086,"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":974556,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":10512,"price":10.76,"value":113109.12,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":73927,"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":974555,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":16165,"price":11.97,"value":193495.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":63415,"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":974554,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-12-10T22:06:02.000Z","date":"2025-12-08","kind":"exercise","planned":true,"acquired":true,"shares":16164,"price":11.1,"value":179420.4,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on August 14, 2025."}],"balance_after":47250,"source":{"system":"sec-edgar","filing":"0001835458-25-000007","document":"form4-12102025_101258.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000007/form4-12102025_101258.xml","form_type":"4"}},{"id":998955,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-11-14T21:35:56.000Z","date":"2025-11-12","kind":"exercise","planned":true,"acquired":false,"shares":19900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":30.93,"expiration_date":"2028-09-19","underlying":"Class A Ordinary Share","underlying_shares":19900},"source":{"system":"sec-edgar","filing":"0001835458-25-000005","document":"form4-11142025_091151.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000005/form4-11142025_091151.xml","form_type":"4"}},{"id":998954,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-11-14T21:35:56.000Z","date":"2025-11-12","kind":"sale","planned":true,"acquired":false,"shares":19900,"price":40.94,"value":814706.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $40.93 and $41.035. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":31086,"source":{"system":"sec-edgar","filing":"0001835458-25-000005","document":"form4-11142025_091151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000005/form4-11142025_091151.xml","form_type":"4"}},{"id":998953,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-11-14T21:35:56.000Z","date":"2025-11-12","kind":"exercise","planned":true,"acquired":true,"shares":19900,"price":30.93,"value":615507.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":50986,"source":{"system":"sec-edgar","filing":"0001835458-25-000005","document":"form4-11142025_091151.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000005/form4-11142025_091151.xml","form_type":"4"}},{"id":1011421,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-10-30T20:47:06.000Z","date":"2025-10-28","kind":"exercise","planned":true,"acquired":false,"shares":100,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable."}],"balance_after":19900,"derivative":{"exercise_price":30.93,"expiration_date":"2028-09-19","underlying":"Class A Ordinary Share","underlying_shares":100},"source":{"system":"sec-edgar","filing":"0001835458-25-000003","document":"form4-10302025_081002.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000003/form4-10302025_081002.xml","form_type":"4"}},{"id":1011420,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-10-30T20:47:06.000Z","date":"2025-10-28","kind":"sale","planned":true,"acquired":false,"shares":100,"price":41,"value":4100.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":31086,"source":{"system":"sec-edgar","filing":"0001835458-25-000003","document":"form4-10302025_081002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000003/form4-10302025_081002.xml","form_type":"4"}},{"id":1011419,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-10-30T20:47:06.000Z","date":"2025-10-28","kind":"exercise","planned":true,"acquired":true,"shares":100,"price":30.93,"value":3093.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":31186,"source":{"system":"sec-edgar","filing":"0001835458-25-000003","document":"form4-10302025_081002.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000183545825000003/form4-10302025_081002.xml","form_type":"4"}},{"id":1049916,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-02","kind":"exercise","planned":false,"acquired":false,"shares":1861,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 2, 2021."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1861},"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049915,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"exercise","planned":false,"acquired":false,"shares":2694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2022."}],"balance_after":2694,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":2694},"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049914,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"exercise","planned":false,"acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, September 1, 2023."}],"balance_after":3500,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049913,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"exercise","planned":false,"acquired":false,"shares":1592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2024."}],"balance_after":4773,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1592},"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049912,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"grant","planned":false,"acquired":true,"shares":39363,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2025."}],"balance_after":39363,"derivative":{"exercise_price":33.49,"expiration_date":"2035-08-31","underlying":"Class A Ordinary Share","underlying_shares":39363},"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049911,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"grant","planned":false,"acquired":true,"shares":12275,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the grant date September 1, 2025."}],"balance_after":12275,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":12275},"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049910,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-02","kind":"tax_withholding","planned":false,"acquired":false,"shares":900,"price":34.28,"value":30852.0,"ownership":{"direct":true},"balance_after":31086,"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049909,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-02","kind":"exercise","planned":false,"acquired":true,"shares":1861,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":31986,"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049908,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":2920,"price":33.49,"value":97790.8,"ownership":{"direct":true},"balance_after":30125,"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049907,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"exercise","planned":false,"acquired":true,"shares":2694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":33045,"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049906,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"exercise","planned":false,"acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":30351,"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1049905,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-09-03T20:45:36.000Z","date":"2025-09-01","kind":"exercise","planned":false,"acquired":true,"shares":1592,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":28601,"source":{"system":"sec-edgar","filing":"0001415889-25-023553","document":"form4-09032025_080932.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925023553/form4-09032025_080932.xml","form_type":"4"}},{"id":1073176,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-08-06T20:30:10.000Z","date":"2025-08-04","kind":"exercise","planned":true,"acquired":false,"shares":18889,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is March 16, 2021."}],"balance_after":2036,"derivative":{"exercise_price":22.89,"expiration_date":"2031-03-15","underlying":"Class A Ordinary Share","underlying_shares":18889},"source":{"system":"sec-edgar","filing":"0001415889-25-021178","document":"form4-08062025_040802.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925021178/form4-08062025_040802.xml","form_type":"4"}},{"id":1073175,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-08-06T20:30:10.000Z","date":"2025-08-04","kind":"sale","planned":true,"acquired":false,"shares":18889,"price":32.89,"value":621259.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":27009,"source":{"system":"sec-edgar","filing":"0001415889-25-021178","document":"form4-08062025_040802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925021178/form4-08062025_040802.xml","form_type":"4"}},{"id":1073174,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-08-06T20:30:10.000Z","date":"2025-08-04","kind":"exercise","planned":true,"acquired":true,"shares":18889,"price":22.89,"value":432369.21,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":45898,"source":{"system":"sec-edgar","filing":"0001415889-25-021178","document":"form4-08062025_040802.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925021178/form4-08062025_040802.xml","form_type":"4"}},{"id":1121487,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-06-05T20:38:56.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":false,"shares":18299,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":18,"expiration_date":"2028-05-22","underlying":"Class A Ordinary Share","underlying_shares":18299},"source":{"system":"sec-edgar","filing":"0001415889-25-015778","document":"form4-06052025_080632.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925015778/form4-06052025_080632.xml","form_type":"4"}},{"id":1121486,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-06-05T20:38:56.000Z","date":"2025-06-03","kind":"sale","planned":true,"acquired":false,"shares":18299,"price":28.8,"value":527011.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":27009,"source":{"system":"sec-edgar","filing":"0001415889-25-015778","document":"form4-06052025_080632.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925015778/form4-06052025_080632.xml","form_type":"4"}},{"id":1121485,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-06-05T20:38:56.000Z","date":"2025-06-03","kind":"exercise","planned":true,"acquired":true,"shares":18299,"price":18,"value":329382.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":45308,"source":{"system":"sec-edgar","filing":"0001415889-25-015778","document":"form4-06052025_080632.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925015778/form4-06052025_080632.xml","form_type":"4"}},{"id":1159414,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance Share Option","published_at":"2025-05-05T20:50:42.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":7606,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Performance Share Options shall vest and become exercisable, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."}],"balance_after":7606,"derivative":{"exercise_price":27.74,"expiration_date":"2035-04-30","underlying":"Class A Ordinary Share","underlying_shares":7606},"source":{"system":"sec-edgar","filing":"0001415889-25-011981","document":"form4-05052025_080539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011981/form4-05052025_080539.xml","form_type":"4"}},{"id":1159413,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance Share Option","published_at":"2025-05-05T20:50:42.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":7368,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Performance Share Options shall vest and become exercisable, if at all, upon the submission to the FDA of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, with certain exceptions."}],"balance_after":7368,"derivative":{"exercise_price":27.74,"expiration_date":"2035-04-30","underlying":"Class A Ordinary Share","underlying_shares":7368},"source":{"system":"sec-edgar","filing":"0001415889-25-011981","document":"form4-05052025_080539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011981/form4-05052025_080539.xml","form_type":"4"}},{"id":1159412,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance Share Unit","published_at":"2025-05-05T20:50:42.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":4786,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance"},{"field":"shares","element":"transactionShares","label":"F2","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"The PSUs shall vest, if at all, upon the approval by the FDA of the commercial sale and marketing in the United States of KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."}],"balance_after":4876,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":4786},"source":{"system":"sec-edgar","filing":"0001415889-25-011981","document":"form4-05052025_080539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011981/form4-05052025_080539.xml","form_type":"4"}},{"id":1159411,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance Share Unit","published_at":"2025-05-05T20:50:42.000Z","date":"2025-05-01","kind":"grant","planned":false,"acquired":true,"shares":4558,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Performance Share Unit (PSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer, based upon the achievement of certain pre-established performance"},{"field":"shares","element":"transactionShares","label":"F2","text":"The award is subject to an earnout percentage of 100%, 75%, 50% or 0%, depending on the date of performance criteria achievement. This figure represents achievement at the 100% earnout performance achievement."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the \"FDA\") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The PSUs shall vest, if at all, upon the submission to the U.S. Food and Drug Administration (the \"FDA\") of a biologics license application for KPL-387 for the treatment of recurrent pericarditis, subject to the Participant's continued employment with the Company, subject to certain exceptions."}],"balance_after":4558,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":4558},"source":{"system":"sec-edgar","filing":"0001415889-25-011981","document":"form4-05052025_080539.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011981/form4-05052025_080539.xml","form_type":"4"}},{"id":1162535,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-05-01T22:24:33.000Z","date":"2025-05-01","kind":"exercise","planned":true,"acquired":false,"shares":13141,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023."}],"balance_after":28909,"derivative":{"exercise_price":17.76,"expiration_date":"2033-08-31","underlying":"Class A Ordinary Share","underlying_shares":13141},"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162534,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-05-01T22:24:33.000Z","date":"2025-05-01","kind":"exercise","planned":true,"acquired":false,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":17.92,"expiration_date":"2029-03-03","underlying":"Class A Ordinary Share","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162533,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-30","kind":"exercise","planned":true,"acquired":false,"shares":21254,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":2471,"derivative":{"exercise_price":16.9,"expiration_date":"2031-04-25","underlying":"Class A Ordinary Share","underlying_shares":21254},"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162532,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-29","kind":"exercise","planned":true,"acquired":false,"shares":22000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.5,"expiration_date":"2030-09-09","underlying":"Class A Ordinary Share","underlying_shares":22000},"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162531,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-29","kind":"exercise","planned":true,"acquired":false,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":15.52,"expiration_date":"2030-03-12","underlying":"Class A Ordinary Share","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162530,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-05-01","kind":"sale","planned":true,"acquired":false,"shares":25141,"price":27.8,"value":698919.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":27009,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162529,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-05-01","kind":"exercise","planned":true,"acquired":true,"shares":13141,"price":17.76,"value":233384.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":52150,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162528,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-05-01","kind":"exercise","planned":true,"acquired":true,"shares":12000,"price":17.92,"value":215040.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":39009,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162527,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-30","kind":"sale","planned":true,"acquired":false,"shares":21254,"price":26.95,"value":572795.3,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":27009,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162526,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-30","kind":"exercise","planned":true,"acquired":true,"shares":21254,"price":16.9,"value":359192.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":48263,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162525,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-29","kind":"sale","planned":true,"acquired":false,"shares":42000,"price":25.61,"value":1075620.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades through a broker-dealer at prices ranging between $25.50 and $25.935. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price."}],"balance_after":27009,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162524,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-29","kind":"exercise","planned":true,"acquired":true,"shares":22000,"price":15.5,"value":341000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":69009,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1162523,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-05-01T22:24:33.000Z","date":"2025-04-29","kind":"exercise","planned":true,"acquired":true,"shares":20000,"price":15.52,"value":310400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on September 3, 2024."}],"balance_after":47009,"source":{"system":"sec-edgar","filing":"0001415889-25-011690","document":"form4-05012025_100529.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011690/form4-05012025_100529.xml","form_type":"4"}},{"id":1163944,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-04-29T20:34:06.000Z","date":"2025-04-26","kind":"exercise","planned":false,"acquired":false,"shares":990,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 26, 2021."}],"balance_after":0,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":990},"source":{"system":"sec-edgar","filing":"0001415889-25-011502","document":"form4-04292025_080403.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011502/form4-04292025_080403.xml","form_type":"4"}},{"id":1163943,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-04-29T20:34:06.000Z","date":"2025-04-26","kind":"tax_withholding","planned":false,"acquired":false,"shares":479,"price":21.365,"value":10233.835,"ownership":{"direct":true},"balance_after":27009,"source":{"system":"sec-edgar","filing":"0001415889-25-011502","document":"form4-04292025_080403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011502/form4-04292025_080403.xml","form_type":"4"}},{"id":1163942,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-04-29T20:34:06.000Z","date":"2025-04-26","kind":"exercise","planned":false,"acquired":true,"shares":990,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":27488,"source":{"system":"sec-edgar","filing":"0001415889-25-011502","document":"form4-04292025_080403.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925011502/form4-04292025_080403.xml","form_type":"4"}},{"id":1174765,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-04-09T20:45:06.000Z","date":"2025-04-07","kind":"exercise","planned":false,"acquired":false,"shares":2694,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 7, 2022."}],"balance_after":2694,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":2694},"source":{"system":"sec-edgar","filing":"0001415889-25-010485","document":"form4-04092025_080402.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010485/form4-04092025_080402.xml","form_type":"4"}},{"id":1174764,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-04-09T20:45:06.000Z","date":"2025-04-07","kind":"tax_withholding","planned":false,"acquired":false,"shares":1303,"price":20.28,"value":26424.84,"ownership":{"direct":true},"balance_after":26498,"source":{"system":"sec-edgar","filing":"0001415889-25-010485","document":"form4-04092025_080402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010485/form4-04092025_080402.xml","form_type":"4"}},{"id":1174763,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-04-09T20:45:06.000Z","date":"2025-04-07","kind":"exercise","planned":false,"acquired":true,"shares":2694,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."}],"balance_after":27801,"source":{"system":"sec-edgar","filing":"0001415889-25-010485","document":"form4-04092025_080402.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010485/form4-04092025_080402.xml","form_type":"4"}},{"id":1179906,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":1592,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on the vesting commencement date of April 1, 2024, and each yearly anniversary thereafter."}],"balance_after":4773,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1592},"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}},{"id":1179905,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"exercise","planned":false,"acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F6","text":"The RSUs vest over a four-year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2023."}],"balance_after":3500,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}},{"id":1179904,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Performance Share Unit","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":14765,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each Performance Share Unit (PSU) represents a contingent right to receive a number of Class A Ordinary Shares of the Issuer based upon the achievement of certain pre-established performance criteria, as certified by the Issuer's Compensation Committee"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"Unless earlier forfeited, each PSU vests and converts into not more than 200% of one Class A Ordinary Share of the Issuer no later than January 30, 2028, unless such date falls on a non-business date, in which case the next business date shall apply."}],"balance_after":14765,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":14765},"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}},{"id":1179903,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Restricted Share Unit","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":7382,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Share Unit (RSU) represents a contingent right to receive one Class A Ordinary Share of the Issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"The RSUs vest over a four year period, with 25% of the RSUs vesting on each yearly anniversary of the date of grant, April 1, 2025."}],"balance_after":7382,"derivative":{"underlying":"Class A Ordinary Share","underlying_shares":7382},"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}},{"id":1179902,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Share Option","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"grant","planned":false,"acquired":true,"shares":29480,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April1, 2025."}],"balance_after":29480,"derivative":{"exercise_price":21.77,"expiration_date":"2035-03-31","underlying":"Class A Ordinary Share","underlying_shares":29480},"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}},{"id":1179901,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":770,"price":21.77,"value":16762.9,"ownership":{"direct":true},"balance_after":25107,"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}},{"id":1179900,"issuer":{"id":1954,"kind":"organization","name":"Kiniksa Pharmaceuticals International, plc","symbol":"KNSA"},"owners":[{"id":2020,"kind":"person","name":"Ragosa Mark","position":1,"cik":"0001835458","reported_name":"Ragosa Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CHIEF FINANCIAL OFFICER"}}],"security":"Class A Ordinary Share","published_at":"2025-04-03T21:04:18.000Z","date":"2025-04-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":847,"price":21.77,"value":18439.19,"ownership":{"direct":true},"balance_after":25877,"source":{"system":"sec-edgar","filing":"0001415889-25-010004","document":"form4-04032025_090414.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1835458/000141588925010004/form4-04032025_090414.xml","form_type":"4"}}],"next_cursor":"2025-04-03T21:04:18.000000Z,1179900"}